[Comment] NICE 2026 guideline for the diagnosis and management of kidney cancer

The Lancet Oncology has published a commentary on the new 2026 NICE guideline for the diagnosis and management of kidney cancer, the sixth most common cancer in UK adults with approximately 13,900 new cases diagnosed annually. The piece highlights that kidney cancer incidence has nearly doubled since the 1990s and is projected to continue rising through 2040, while UK five-year relative survival remains below the European average. A key challenge underscored by the guideline is early detection, as 87% of UK patients with stage 1a disease are diagnosed incidentally without presenting relevant symptoms. The commentary also draws attention to significant regional variation in the provision of kidney cancer care across England and Wales, signaling a need for standardized, guideline-driven practice.